Our centre combines clinical and laboratory expertise to tackle autoimmune, inflammatory, and immune deficiency diseases. Starting from a genetic discovery platform, we aim to understand precisely how the immune system goes wrong in each individual patient to cause disease. This approach will make diagnoses more accurate and tailor treatment to each patient. The centre's approach should provide a template for the implementation of genomics and personalized medicine into routine clinical practice
Understanding Gene Regulation In Disease Using High Throughput Sequencing
Funder
National Health and Medical Research Council
Funding Amount
$415,218.00
Summary
While genetics refers to the gene sequence, or DNA code, epigenetics refers to all the other factors that control how and when each gene is expressed. New technologies with the ability to sequencing billions of bases of DNA are now being used to study epigenetics. However the data sets are vast and complex. I use statistical and computational approaches in the emerging field of bioinformatics to make sense of this data and relate genome wide disruption of epigenetic marks to diseases.
The Landscape Of Cancer Genes And Associations With Prognosis In Breast Cancer Diagnosed In Premenopausal Women
Funder
National Health and Medical Research Council
Funding Amount
$700,512.00
Summary
Using state of the art technology, the purpose of this project is understand the implications of known cancer mutations in breast cancer diagnosed in premenopausal ER-positive breast cancer. Mutations are abnormalities in the DNA of genes that can provide a signal for uncontrolled growth, a hallmark of cancer. The unique aspect of this project is use of tissue samples from patients who were diagnosed with breast cancer at a young age. This information will help us develop new treatments.
Diagnosing Hereditary Myopathies And Dystrophies With RNA Sequencing: Translating Research Innovations Into Diagnostic Practice
Funder
National Health and Medical Research Council
Funding Amount
$279,725.00
Summary
Despite recent advances in genetic testing, more than 50% of patients with hereditary neuromuscular disorders remain undiagnosed. This project aims to apply an alternative and the newest form of Next Generation Sequencing (NGS) testing strategy known as transciptome or RNA sequencing to clinical practice to further investigate patients who have remained undiagnosed despite WES and WGS.
GENETIC AND FUNCTIONAL CHARACTERISATION OF ERAP1 VARIANTS ASSOCIATED WITH ANKYLOSING SPONDYLITIS.
Funder
National Health and Medical Research Council
Funding Amount
$133,351.00
Summary
Ankylosing Spondylitis is a progressive arthritis which affects the back and causes the back joints to fuse. The project seeks to investigate the role of the ERAP1 protein and the gene which is the blueprint for the ERAP1 protein in causing Ankylosing Spondylitis. This will be through resequencing the gene, investigating the action of the different ERAP1 proteins and the effect of ERAP1 deficiency in mice.
Discovering The Cell Of Origin For Rare Ovarian Cancers
Funder
National Health and Medical Research Council
Funding Amount
$599,438.00
Summary
Ovarian cancer has many different varieties, and even though they all grow at the ovary, for some types we don't know the cell where the cancer starts. Using novel sequencing methods, this study will find the tissue of origin for two rare subtypes. This finding will help us to develop appropriate pre-clinical models that we can use to test emerging cancer therapies. Identifying the cell of origin will provide key insights into early detection or even prevention of these rare but deadly diseases.
Clonal Evolution In Myelodysplasia And Acute Myeloid Leukaemia Following Azacitidine
Funder
National Health and Medical Research Council
Funding Amount
$853,005.00
Summary
The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a spectrum of clinically heterogeneous malignancies that remain incurable in the vast majority of patients. Whilst the DNA mutations underpinning the initiation/maintenance of these malignancies are largely known we have little insight into how these mutations alter response to therapy. Using a range of sophisticated cutting edge technologies we will study how these DNA mutations evolve over the course of treatment.
New Technologies For Hierarchial Shotgun Sequencing Of Recalcitrant And Repetitive DNA
Funder
National Health and Medical Research Council
Funding Amount
$79,750.00
Summary
Many repetitive regions of genomes are difficult to sequence and to assemble. �Sequencing Aided by Mutation� (SAM) is a new sequencing technology, which overcomes many of the difficulties that hinder current sequencing methods. SAM involves forming randomly mutated copies of the target DNA. These copies can then be sequenced and new mathematical tools permit the original target sequence to be revealed from the mutant copies. Here the technology will be developed to aid sequencing of long repetit ....Many repetitive regions of genomes are difficult to sequence and to assemble. �Sequencing Aided by Mutation� (SAM) is a new sequencing technology, which overcomes many of the difficulties that hinder current sequencing methods. SAM involves forming randomly mutated copies of the target DNA. These copies can then be sequenced and new mathematical tools permit the original target sequence to be revealed from the mutant copies. Here the technology will be developed to aid sequencing of long repetitive DNA fragments in genomes.Read moreRead less
MECHANISMS AND MARKERS OF TUBERCULOSIS TRANSMISSION WITHIN AUSTRALIA
Funder
National Health and Medical Research Council
Funding Amount
$799,978.00
Summary
Tuberculosis (TB) kills nearly 2 million people each year. The emergence of drug resistant TB in the Asia-Pacific region poses a particular threat to Australia, due to frequent population mixing and ongoing TB transmission that may facilitate its spread within vulnerable communities. The proposed study will develop advanced tools to monitor and limit TB transmission within Australia. It will also provide novel insight into the evolution of the global TB epidemic and key factors that sustain it.
RNA viruses are one of the last frontiers for globally significant infections. There ability to rapidly hide from the host's immune response and cause additional infections has made the ability to make vaccines very difficult. By studying patients that naturally and rapidly clear multiple infections we have identified strategies to conquer these highly divergent viruses. We are currently dedicated to trying to understand how we can mold this knowledge into a protective vaccine.